1. Home
  2. CNF vs GBIO Comparison

CNF vs GBIO Comparison

Compare CNF & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CNF

CNFinance Holdings Limited each representing twenty (20)

HOLD

Current Price

$5.66

Market Cap

43.5M

Sector

Finance

ML Signal

HOLD

Logo Generation Bio Co.

GBIO

Generation Bio Co.

HOLD

Current Price

$5.66

Market Cap

36.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNF
GBIO
Founded
1999
2016
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
43.5M
36.3M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
CNF
GBIO
Price
$5.66
$5.66
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$8.88
AVG Volume (30 Days)
9.4K
89.9K
Earning Date
02-27-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$50,241,013.00
$15,270,000.00
Revenue This Year
$252.34
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.36
$3.00
52 Week High
$13.90
$9.96

Technical Indicators

Market Signals
Indicator
CNF
GBIO
Relative Strength Index (RSI) 54.49 54.70
Support Level $4.00 $5.41
Resistance Level $4.80 $5.72
Average True Range (ATR) 0.49 0.13
MACD 0.03 0.01
Stochastic Oscillator 82.96 79.27

Price Performance

Historical Comparison
CNF
GBIO

About CNF CNFinance Holdings Limited each representing twenty (20)

CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Share on Social Networks: